B. Douglas Smith, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Room 246, CRB1, Baltimore, MD 21231-1000, USA. Disclosure: The authors have no relevant ...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent ...
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
Factors associated with occurrence of acute leukemias and myelodyplastic neoplasms as seen at the Kenyatta National Hospital, Nairobi, Kenya. Real-world adherence and tolerability of FLT3 inhibitors ...
Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results